» Articles » PMID: 19747140

Targeting Epidermal Growth Factor Receptor in Solid Tumors: Critical Evaluation of the Biological Importance of Therapeutic Monoclonal Antibodies

Overview
Journal Curr Med Chem
Specialty Chemistry
Date 2009 Sep 15
PMID 19747140
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous cellular pathways have a significant impact in the growth and metastatic potential of tumors. Essential element of such pathways is the epidermal growth factor receptor (EGFR), a member of the HER family of receptor tyrosine kinases. One of the most important issues in cancer, which attracted the attention of clinical oncologists, is the potential use of targeted therapies. EGFR signaling pathway is implicated in the control of cell survival, proliferation, metastasis and angiogenesis. EGFR is, therefore, an appealing target for molecular-targeted cancer therapy as it is expressed in a variety of solid tumors (colorectal, breast, head and neck, etc.). Receptor antagonists that target EGFR have already been of high interest for a number of years. Multiple therapeutic strategies have been developed to target EGFR, including monoclonal antibodies (mAbs), tyrosine kinase inhibitors (TKIs), ligand-toxin conjugates, and antisense oligonucleotides. In particular, mAbs block ligand from binding to the extracellular domain of the receptor. Two mAbs that block EGFR (erbB1), cetuximab and panitumumab, have been approved by FDA. Cetuximab is a chimeric IgG1 anti-EGFR monoclonal antibody, whereas panitumumab is a fully human IgG2 anti-EGFR monoclonal antibody. This review highlights the cellular effects of EGFR blockade by mAbs and their relationship to therapeutic efficacy and biological significance.

Citing Articles

Redox signaling-mediated tumor extracellular matrix remodeling: pleiotropic regulatory mechanisms.

Liu G, Li B, Qin S, Nice E, Yang J, Yang L Cell Oncol (Dordr). 2023; 47(2):429-445.

PMID: 37792154 DOI: 10.1007/s13402-023-00884-9.


A chimeric antigen receptor uniquely recognizing MICA/B stress proteins provides an effective approach to target solid tumors.

Goulding J, Yeh W, Hancock B, Blum R, Xu T, Yang B Med. 2023; 4(7):457-477.e8.

PMID: 37172578 PMC: 10524375. DOI: 10.1016/j.medj.2023.04.004.


Potential Role of Phytochemicals Against Matrix Metalloproteinase Induced Breast Cancer; An Explanatory Review.

Khan Y, Uttra A, Qasim S, Mallhi T, Alotaibi N, Rasheed M Front Chem. 2021; 8:592152.

PMID: 33520928 PMC: 7843438. DOI: 10.3389/fchem.2020.592152.


COL1A1: A potential therapeutic target for colorectal cancer expressing wild-type or mutant KRAS.

Zhang Z, Fang C, Wang Y, Zhang J, Yu J, Zhang Y Int J Oncol. 2018; 53(5):1869-1880.

PMID: 30132520 PMC: 6192778. DOI: 10.3892/ijo.2018.4536.


Targeting the Epidermal Growth Factor Receptor in Addition to Chemotherapy in Patients with Advanced Pancreatic Cancer: A Systematic Review and Meta-Analysis.

Chiramel J, Backen A, Pihlak R, Lamarca A, Frizziero M, Tariq N Int J Mol Sci. 2017; 18(5).

PMID: 28445400 PMC: 5454822. DOI: 10.3390/ijms18050909.